The Rise and Fall of Bone Morphogenetic Protein

BACKGROUND CONTEXT: The United States Food and Drug Administration (FDA) issued a warning in 2008 against the use of recombinant bone morphogenetic protein (BMP). Patient demographics and economic data associated with the insertion of BMP are critical to understanding and improving health care utilization. Given the increasing focus on health care utilization and value-based care, it is essential to understand the demographic and economic data surrounding utilization of BMP.

from Sports Medicine via xlomafota13 on Inoreader http://ift.tt/2gby1zs
via IFTTT